Cytokinetics, Incorporated
CYTK
Clasificación en acciones
#2266
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Precio por acción
$63.98
Capitalización bursátil
$8.89B
Cambio (1 día)
2.12%
Cambio (1 año)
7.80%
País
US
Comercio Cytokinetics, Incorporated (CYTK)
Categoría
Healthcare
Ratio P/B de Cytokinetics, Incorporated (CYTK)
Ratio P/B al October 2026 TTM: -48.29
Según los informes financieros más recientes y el precio de las acciones de Cytokinetics, Incorporated, el ratio P/B actual (TTM) es -48.29. Al final de 2023, el ratio P/B era -20.86.
Historial del ratio P/B de Cytokinetics, Incorporated desde 2000 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | -48.29 | 24.11% |
| 2024 | -38.91 | 86.53% |
| 2023 | -20.86 | -45.31% |
| 2022 | -38.14 | -365.43% |
| 2021 | 14.37 | 21.52% |
| 2020 | 11.83 | -121.17% |
| 2019 | -55.85 | -521.16% |
| 2018 | 13.26 | 261.78% |
| 2017 | 3.67 | -28.73% |
| 2016 | 5.14 | -12.77% |
| 2015 | 5.90 | 89.76% |
| 2014 | 3.11 | -4.59% |
| 2013 | 3.26 | 224.44% |
| 2012 | 1.00 | -28.86% |
| 2011 | 1.41 | -25.82% |
| 2010 | 1.90 | 15.51% |
| 2009 | 1.65 | -41.79% |
| 2008 | 2.83 | 25.55% |
| 2007 | 2.25 | -12.56% |
| 2006 | 2.58 | 1.70% |
| 2005 | 2.53 | 34.40% |
| 2004 | 1.88 | -663.83% |
| 2003 | -0.33 | -27.78% |
| 2002 | -0.46 | -24.36% |
| 2001 | -0.61 | -14.08% |
| 2000 | -0.71 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -112.94% |
US
|
|
| 13.2547 | -127.45% |
US
|
|
| 4.208 | -108.71% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -112.80% |
NL
|
